He received his Ph.D. in Organic Chemistry at the University of Toledo and did his postdoctoral studies in Chemical Biology at Portland State University and Stanford University. Alhamadsheh’s research group employs an interdisciplinary approach to study protein amyloidosis. His group recently developed AG10, a small molecule that prevents amyloidogenesis of the plasma protein Transthyretin. Alhamadsheh’s group is also developing novel technologies to enhance the in vivo half-life of therapeutic peptides. These technologies would decrease the production cost of therapeutic peptides and increase the clinical success rate. Dr. Alhamadsheh is the recipient of New Investigator Award from the American Association of Colleges of Pharmacy. He is a co-founder of Eidos Therapeutics and has authored four patents and 18 articles in peer-reviewed journals.